Trials / Unknown
UnknownNCT02166151
Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Rabin Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The study is designed to assess the efficacy and safety of monthly injections of Omalizumab 150 mg for 3 consecutive months, in patients with chronic idiopathic urticaria, unresponsive to convetional therapy by antihistamins or oral corticosteroids.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Omalizimab | Omalizimab 150 mg S.C. once a month for consecutive 3 months |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2016-06-01
- Completion
- 2016-06-01
- First posted
- 2014-06-18
- Last updated
- 2014-06-18
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT02166151. Inclusion in this directory is not an endorsement.